Table 1.

Summary table of clinical trials and case reports published the past 18 months (for review of studies prior to January 2007, see Boxer and Boeve [18*] and Huey et al. [20]).

References	Subjects	Medication	Study Type	Duration	Main Findings	Limitations
Diehl-Schmid et al. [21]	16 (bvFTD and tvFTD)	Memantine 20mg/day	All participants given open-label treatment	6 months	No improvement in behavior; worsening of cognitive function	Small sample size, no control group
Kertesz et al. [22*]	36 (bvfTD and PPA)	Galantamine 16–24 mg/day	All participants given open-label treatment, followed by 8-week, double- lind,placebo- controlled, randomized withdrawal	18 weeks	No improvement in bvFTD, trend of efficacy in PPA	Possible admixture of AD patients in PPA group
Cruz et al. [23]	1 (bvFTD)	Topiramate 100mg b.i.d.	Case report	6 months	Reduction of alcohol abuse but not other compulsive behaviors	Case report, alcoholism uncommon in FTD
Anneser et al. [24]	1 (FTD- MND)	Sertraline 50 mg b.i.d.	Case report	n/a	Successful treatment of inappropriate sexual behavior	Case report
Swanberg et al. [25]	3 (bvFTD)	Memantine 10 mg b.i.d.	Case series, all patients given treatment for 3 months	3 months	All 3 patients had improved NPI score, specifically apathy, agitation, and anxiety	Sample size